Orally Active Peptidomimetic RGD Analogs that are Glycoprotein IIb/IIIa Antagonists

Abstract

Peptidomimetic RGD (Arg-Gly-Asp) analogs, which bind to glycoprotein (GP) IIb/IIIa on the surface of activated platelets, have been shown to inhibit platelet aggregation. Consequently, such RGD analogs can be used for the treatment of unstable angina pectoris and myocardial infarction. However, the low oral bioavailability for this class of compounds has been hindering their clinical development. Although many factors affect the oral activity of a drug, the limited membrane permeability of RGD analogs due to charge and high polarity is thought to be a major factor leading to the low oral activity of such compounds. Another factor is the metabolic lability of some such RGD analogs in the presence of proteases and peptidases. During the last 5 years, major progress has been made in the development of orally active RGD analogs. To improve the metabolic stability of RGD analogs, N-alkylation and C-terminal modification methods have been used successfully. To improve the membrane permeability of RGD analogs, two major strategies have been used. The first one is the strategy of prodrug. Along this line, simple ester prodrugs, double prodrugs, triple prodrugs, and cyclic prodrugs have been prepared with improved membrane permeability and oral activity. The second approach used is the de novo design of centrally constrained RGD analogs with improved oral bioavailability while maintaining the desired potency against GP IIb/IIIa. The lessons learned from the modification of RGD analogs could also help the future design of other peptidomimetic drugs with improved oral bioavailability.

AFPep: an anti-breast cancer peptide that is orally active

“…Panel (b) AFPep (100 lg) (¤) or saline (s) was administered by subcutaneous injection once daily for 23 days to rats (n=20) that had been exposed to a carcinogen (MNU). varying degrees of success to circumvent these susceptibilities [4,13]. Cyclization is one of those strategies because it should negate susceptibility to exopeptidases, and oftentimes stabilizes the pharmacophoric region of a peptide.…”

Integrin αVβ3as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo

“…RGD-analogs can be designed or modified to increase their oral bioavailability 35 and their transepithelial transport. 36 Taken together, our data suggest the possibility to use RGD peptidomimetics for the treatment of ␣ v ␤ 3 -dependent pathologies associated with AIDS.…”

In vitro assessment of the cytotoxic effects of novel RGD analogues

“…This is largely due to the metabolic lability of this class of compounds in the presence of proteases and peptidases and because of their high polarity and charge. Wang et al [17] published a detailed review of peptidomimetic analogues of RGD and the strategies used to enhance their bioavailability.…”